journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/28334412/missing-author-initial-in-byline
#1
(no author information available yet)
No abstract text is available yet for this article.
March 23, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28334399/association-of-hiv-status-with-local-immune-response-to-anal-squamous-cell-carcinoma-implications-for-immunotherapy
#2
Elizabeth L Yanik, Genevieve J Kaunitz, Tricia R Cottrell, Farah Succaria, Tracee L McMiller, Maria L Ascierto, Jessica Esandrio, Haiying Xu, Aleksandra Ogurtsova, Toby Cornish, Evan J Lipson, Suzanne L Topalian, Eric A Engels, Janis M Taube
Importance: The programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway play an important immunosuppressive role in cancer and chronic viral infection, and have been effectively targeted in cancer therapy. Anal squamous cell carcinoma (SCC) is associated with both human papillomavirus and HIV infection. To date, patients with HIV have been excluded from most trials of immune checkpoint blocking agents, such as anti-PD-1 and anti-PD-L1, because it was assumed that their antitumor immunity was compromised compared with immunocompetent patients...
March 23, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28334365/effect-of-kit-and-pdgfra-mutations-on-survival-in-patients-with-gastrointestinal-stromal-tumors-treated-with-adjuvant-imatinib-an-exploratory-analysis-of-a-randomized-clinical-trial
#3
Heikki Joensuu, Eva Wardelmann, Harri Sihto, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Jörg T Hartmann, Daniel Pink, Silke Cameron, Peter Hohenberger, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Bengt Nilsson, Raija Kallio, Jouni Junnila, Aki Vehtari, Peter Reichardt
Importance: Little is known about whether the duration of adjuvant imatinib influences the prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor α (PDGFRA) mutations. Objective: To investigate the effect of KIT and PDGFRA mutations on recurrence-free survival (RFS) in patients with gastrointestinal stromal tumors (GISTs) treated with surgery and adjuvant imatinib. Design, Setting, and Participants: This exploratory study is based on the Scandinavian Sarcoma Group VIII/Arbeitsgemeinschaft Internistische Onkologie (SSGXVIII/AIO) multicenter clinical trial...
March 23, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28334363/risk-of-bias-and-heterogeneity
#4
Hirotaka Matsumoto, Yuki Kataoka
No abstract text is available yet for this article.
March 23, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28334361/defining-the-impact-of-adjuvant-therapy-in-molecularly-defined-subsets-of-gastrointestinal-stromal-tumor-from-lumping-to-splitting
#5
Michael C Heinrich, Christopher L Corless, George D Demetri
No abstract text is available yet for this article.
March 23, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28334347/risk-of-bias-and-heterogeneity-reply
#6
Mizuki Nishino, Anita Giobbie-Hurder, F Stephen Hodi
No abstract text is available yet for this article.
March 23, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28334337/birth-outcomes-among-adolescent-and-young-adult-cancer-survivors
#7
Chelsea Anderson, Stephanie M Engel, Jennifer E Mersereau, Kristin Z Black, William A Wood, Carey K Anders, Hazel B Nichols
Importance: Cancer diagnosis and treatment may adversely affect reproductive outcomes among female cancer survivors. Objective: To compare the birth outcomes of adolescent and young adult cancer survivors (AYA [diagnosed at ages 15-39 years]) with those of women without a cancer diagnosis. Design, Setting, and Participants: The North Carolina Central Cancer Registry (CCR) was used to identify female AYA cancer survivors diagnosed from January 2000 to December 2013; CCR records were linked to statewide birth certificate files from January 2000 to December 2014 to identify postdiagnosis live births to AYA survivors (n = 2598)...
March 23, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28334324/understanding-the-genetic-landscape-of-small-cell-carcinoma-of-the-urinary-bladder-and-implications-for-diagnosis-prognosis-and-treatment-a-review
#8
Erik J Kouba, Liang Cheng
Importance: Small cell carcinoma of the urinary bladder is a rare and aggressive neuroendocrine tumor of the urinary bladder. Although research has been performed since the first case was reported in 1981, most of our understanding of the disease treatments has been extrapolated from small cell carcinoma of the lung. However, current data on patient survival have been stagnant. Observations: With the advent of advanced molecular diagnostic methods, a new potential for understanding the origin and treatment of small cell carcinoma of the urinary bladder has become evident...
March 23, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28301662/brain-metastases-in-newly-diagnosed-breast-cancer-a-population-based-study
#9
Allison M Martin, Daniel N Cagney, Paul J Catalano, Laura E Warren, Jennifer R Bellon, Rinaa S Punglia, Elizabeth B Claus, Eudocia Q Lee, Patrick Y Wen, Daphne A Haas-Kogan, Brian M Alexander, Nancy U Lin, Ayal A Aizer
Importance: Population-based estimates of the incidence and prognosis of brain metastases at diagnosis of breast cancer are lacking. Objective: To characterize the incidence proportions and median survivals of patients with breast cancer and brain metastases at the time of cancer diagnosis. Design, Setting, and Participants: Patients with breast cancer and brain metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute...
March 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28301652/to-protect-our-patients-with-prostate-cancer
#10
Daniel E Spratt
No abstract text is available yet for this article.
March 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28301631/androgen-receptor-function-and-androgen-receptor-targeted-therapies-in-breast-cancer-a-review
#11
Miho Kono, Takeo Fujii, Bora Lim, Meghan Sri Karuturi, Debasish Tripathy, Naoto T Ueno
Importance: The androgen receptor (AR) pathway is emerging as a potential therapeutic target in breast cancer. To date, AR-targeted drugs have been approved only for treatment of prostate cancer; however, AR-targeted treatment for breast cancer is an area of active investigation. Through review of preclinical studies, retrospective clinical studies, and clinical trials, we examined the biology of AR and AR-related pathways, the potential for AR-targeted therapies in breast cancer, and potential biomarkers for AR-targeted treatments...
March 16, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28278348/a-prospective-multi-institutional-pathologist-based-assessment-of-4-immunohistochemistry-assays-for-pd-l1-expression-in-non-small-cell-lung-cancer
#12
David L Rimm, Gang Han, Janis M Taube, Eunhee S Yi, Julia A Bridge, Douglas B Flieder, Robert Homer, William W West, Hong Wu, Anja C Roden, Junya Fujimoto, Hui Yu, Robert Anders, Ashley Kowalewski, Christopher Rivard, Jamaal Rehman, Cory Batenchuk, Virginia Burns, Fred R Hirsch, Ignacio I Wistuba
Importance: Four assays registered with the US Food and Drug Administration (FDA) detect programmed cell death ligand 1 (PD-L1) to enrich for patient response to anti-programmed cell death 1 and anti-PD-L1 therapies. The tests use 4 separate PD-L1 antibodies on 2 separate staining platforms and have their own scoring systems, which raises questions about their similarity and the potential interchangeability of the tests. Objective: To compare the performance of 4 PD-L1 platforms, including 2 FDA-cleared assays, 1 test for investigational use only, and 1 laboratory-developed test...
March 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28278338/pediatric-palliative-care-a-shared-priority
#13
Jennifer W Mack
No abstract text is available yet for this article.
March 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28278333/adjuvant-treatment-for-high-risk-clear-cell-renal-cancer-updated-results-of-a-high-risk-subset-of-the-assure-randomized-trial
#14
Naomi B Haas, Judith Manola, Janice P Dutcher, Keith T Flaherty, Robert G Uzzo, Michael B Atkins, Robert S DiPaola, Toni K Choueiri
Importance: Given recently published results of a 750-patient adjuvant sunitinib trial showing improved disease-free survival (DFS), the appropriate strategy for treating high-risk patients is unclear. We sought to determine whether there is improved disease-free survival benefit to taking the active drug in patients with high-risk (pT3, pT4, node-positive) clear cell renal cancer (ccRCC) in the ASSURE trial (adjuvant sunitinib or sorafenib vs placebo in resected unfavorable renal cell carcinoma [RCC]), the largest adjuvant trial published to date...
March 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28278329/patients-and-parents-needs-attitudes-and-perceptions-about-early-palliative-care-integration-in-pediatric-oncology
#15
Deena R Levine, Belinda N Mandrell, April Sykes, Michele Pritchard, Deborah Gibson, Heather J Symons, David Wendler, Justin N Baker
Importance: Early palliative care integration for cancer patients is now touted as the optimal care model, yet significant barriers often prevent its implementation. A perceived barrier, especially for pediatric oncology patients, is the notion that patients and their families may not need or want palliative care involvement early in the disease trajectory. Objective: To determine the perception of symptom burden early in treatment and assess attitudes toward early integration of palliative care in pediatric oncology patient-parent pairs...
March 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28278328/planning-adjuvant-trials-when-regimens-effective-for-patients-with-advanced-disease-don-t-work-in-the-adjuvant-setting-paradigms-lost
#16
Bhupinder Mann, James Zwiebel
No abstract text is available yet for this article.
March 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28278319/association-of-the-timing-of-pregnancy-with-survival-in-women-with-breast-cancer
#17
Javaid Iqbal, Eitan Amir, Paula A Rochon, Vasily Giannakeas, Ping Sun, Steven A Narod
Importance: Increasing numbers of women experience pregnancy around the time of, or after, a diagnosis of breast cancer. Understanding the effect of pregnancy on survival in women with breast cancer will help in the counseling and treatment of these women. Objective: To compare the overall survival of women diagnosed with breast cancer during pregnancy or in the postpartum period with that of women who had breast cancer but did not become pregnant. Design, Setting, and Participants: This population-based, retrospective cohort study linked health administrative databases in Ontario, Canada, comprising 7553 women aged 20 to 45 years at the time of diagnosis with invasive breast cancer, from January 1, 2003, to December 31, 2014...
March 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28278316/assays-for-pd-l1-expression-do-all-roads-lead-to-rome
#18
Gabriel L Sica, Suresh S Ramalingam
No abstract text is available yet for this article.
March 9, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28253395/rapidly-enlarging-thyroid-mass-in-a-patient-with-history-of-multiple-cancers
#19
Halis Kaan Akturk, Robert Smallridge, John Casler
No abstract text is available yet for this article.
March 2, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28253394/clinical-and-radiologic-responses-to-cladribine-for-the-treatment-of-erdheim-chester-disease
#20
Gaurav Goyal, Mithun V Shah, Timothy G Call, Mark R Litzow, William J Hogan, Ronald S Go
Importance: While cladribine is best known for the treatment of hairy cell leukemia and other lymphoid cancers, it also has activity against myeloid neoplasms, such as Erdheim-Chester disease (ECD). Objective: To assess the efficacy of cladribine (2-chloro-2'-deoxyadenosine) in the treatment of ECD. Design, Setting, and Participants: This study was a single-institution retrospective medical record review from January 1, 1998, to April 6, 2016, at a tertiary academic medical center...
March 2, 2017: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"